JO
TBPH icon

John Overdeck’s Theravance Biopharma TBPH Stock Holding History

John Overdeck’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8M Sell
1,225,587
-32,910
-3% -$545K 0.02% 1030
2026
Q1 		$20.4M Buy
1,258,497
+721,156
+134% +$12.8M 0.02% 934
2025
Q4 		$10.1M Buy
537,341
+306,069
+132% +$5.08M 0.01% 1121
2025
Q3 		$3.38M Buy
231,272
+213,480
+1,200% +$2.7M 0.01% 1762
2025
Q2 		$196K Buy
+17,792
New +$173K ﹤0.01% 2921
2024
Q3 		– Sell
-49,523
Closed -$420K – 3331
2024
Q2 		$420K Buy
+49,523
New +$447K ﹤0.01% 2443
2024
Q1 		– Sell
-38,939
Closed -$438K – 3382
2023
Q4 		$438K Buy
+38,939
New +$392K ﹤0.01% 2531
2023
Q3 		– Sell
-58,058
Closed -$601K – 3212
2023
Q2 		$601K Sell
58,058
-298,809
-84% -$3.3M ﹤0.01% 2242
2023
Q1 		$3.87M Sell
356,867
-605,959
-63% -$6.41M 0.01% 1032
2022
Q4 		$10.8M Buy
962,826
+309,956
+47% +$3.26M 0.03% 531
2022
Q3 		$6.62M Buy
+652,870
New +$6.12M 0.02% 646
2022
Q2 		– Sell
-149,240
Closed -$1.43M – 2924
2022
Q1 		$1.43M Buy
149,240
+114,174
+326% +$1.12M ﹤0.01% 1509
2021
Q4 		$387K Buy
+35,066
New +$306K ﹤0.01% 3464
2021
Q2 		– Sell
-40,962
Closed -$836K – 4546
2021
Q1 		$836K Buy
+40,962
New +$779K ﹤0.01% 2479
2020
Q4 		– Sell
-39,519
Closed -$584K – 3747
2020
Q3 		$584K Sell
39,519
-132,531
-77% -$2.48M ﹤0.01% 2125
2020
Q2 		$3.61M Buy
+172,050
New +$4.42M 0.02% 804
2018
Q4 		– Sell
-15,656
Closed -$511K – 3506
2018
Q3 		$511K Buy
+15,656
New +$427K ﹤0.01% 2434
2017
Q1 		– Sell
-26,931
Closed -$859K – 3311
2016
Q4 		$859K Buy
26,931
+16,299
+153% +$506K ﹤0.01% 2117
2016
Q3 		$385K Buy
+10,632
New +$296K ﹤0.01% 2592
2015
Q1 		– Sell
-46,775
Closed -$698K – 2850
2014
Q4 		$698K Buy
+46,775
New +$815K ﹤0.01% 1555

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

John Overdeck's TBPH Position: Q2 2026 in Review

John Overdeck reduced its Theravance Biopharma (TBPH) stake by 2.6% in Q2 2026, selling an estimated $545K and leaving 1,225,587 shares worth $20.8M. The position accounts for 0.02% of the portfolio, ranked #1030.

John Overdeck first reported a position in TBPH in Q4 2014 and has held it in 20 quarters since. 178 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • John Overdeck held 1,225,587 shares of Theravance Biopharma worth $20.8M as of Q2 2026.
  • John Overdeck sold 32,910 Theravance Biopharma shares in Q2 2026, an estimated $545K.
  • Theravance Biopharma made up 0.02% of John Overdeck's portfolio in Q2 2026, its #1030 holding.
  • John Overdeck first reported a position in Theravance Biopharma in Q4 2014 and has held it in 20 quarters since.
  • 178 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.